Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve cognitive performance as compared to placebo.

Key facts

Study ID
NCT00191009
Run by
Eli Lilly and Company
People needed
124
Starts
2003-10-01
Expected to finish
2006-01-01
Last updated by the study team
2007-11-06

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.